Q-omics provides the consensus-scored TMEM86A profile across patient tissues and cancer cell-line models. TMEM86A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM86A is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, TMEM86A RNA expression shows 18,444 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRP, and GBM as cancer lineages where TMEM86A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM86A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM86A survival associations across molecular data types. TMEM86A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM86A RNA expression–survival associations across cancer types. High TMEM86A expression shows unfavorable associations in ACC, COAD and MESO, but favorable associations in UVM, DLBC and CESC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM86A RNA expression.
This table summarizes TMEM86A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM86A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM86A shows lower tumor expression in KIRP, KIRC and KICH and higher tumor expression in STAD, HNSC and BRCA. The KIRP box plot shows higher TMEM86A RNA expression in normal versus tumor tissue (log2 FC = −1.422, t-test p < 0.001).
This table shows molecular features associated with TMEM86A in patient tissues and cancer cell lines. In patient samples, TMEM86A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM86A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
